


 Cite this: *RSC Adv.*, 2021, 11, 31967

Discovery of catalytic-site-fluorescent probes for tracing phosphodiesterase 5 in living cells†

 Meiying Qiu,^{‡a} Deyan Wu,^{‡ab} Yi-You Huang,^{ab} Yue Huang,^a Qian Zhou,^a Yijing Tian,^a Lei Guo,^{id a} Yuqi Gao^{id *a} and Hai-Bin Luo^{id *ab}

Small molecule fluorescent probes provide a powerful labelling technology to enhance our understanding of particular proteins. However, the discovery of a proper fluorescent probe for detecting PDE5 is still a challenge due to the highly conservative structure of the catalytic domain in the phosphodiesterase (PDE) families. Herein, we identified probes based on the key amino residues in the ligand binding pocket of PDE5 and catalytic-site-fluorescent probes PCO2001–PCO2003 were well designed and synthesized. Among them, PCO2003 exhibited extraordinary fluorescence properties and the ability to be applied to PDE5 visualization in live cells as well as in pulmonary tissue slices, demonstrating the location and expression level of PDE5 proteins. Overall, the environment-sensitive “turn-on” probe is economical, convenient and rapid for PDE5 imaging, implying that the catalytic-site-fluorescent probe will have a variety of future applications in pathological diagnosis as well as drug screening.

 Received 18th August 2021
 Accepted 20th September 2021

DOI: 10.1039/d1ra06247f

rsc.li/rsc-advances

Introduction

For humans, information visible to the naked eye is always more convective. It is usually impossible to obtain visual signals of most biomolecules, cells and organisms by direct observation. Currently, opportunities to visualize many physiological processes have been provided by labelling techniques, such as the isotope method, dye staining and fluorescent protein labelling.¹ More recently, small molecule fluorescent probes have emerged as a powerful labelling technology to enhance our understanding of particular proteins of interest because of their high sensitivity, structural flexibility and simple operation, compared with other types of probes for non-invasive imaging such as positron emission tomography (PET) or nuclear magnetic resonance (NMR).² Comparing with conventional immunofluorescence imaging or fluorescent protein labeling imaging, it's more convenient and superior to use non-invasive fluorescent probes to detect proteins in live cells without the assistance of specific antibodies applied in fixed cells or complicated protein tag techniques.³ So far, they have been widely used in protein labelling, bioactive molecule (ROS, H₂S, NO, DNA, RNA, *etc*)^{4–7} detection and enzyme direct imaging,^{8–11}

for dynamic tracing significant biological processes in cells or even live animals.

Phosphodiesterases (PDEs) are a series of vital enzymes that perform unique roles in the signal transduction and duration for many physiopathological processes,¹² by maintaining the intracellular levels of cyclic nucleotides (cAMP and cGMP) which are involved in cell proliferation and differentiation, cell-cycle regulation, gene expression, inflammation, apoptosis, and metabolism. PDE5 is one of the PDEs family members which specifically catalyses the hydrolysis of cGMP. Currently, several PDE5 inhibitors have been approved for several diseases, such as erectile dysfunction and pulmonary arterial hypertension (PAH).^{13,14} And recently, the role of PDE5 in idiopathic pulmonary fibrosis (IPF) has attracted much attention.^{15,16} It is highly desirable to develop fluorescent probes that can detect and image PDE5 in living biosystems accurately and selectively.

To date, phosphodiesterase activity based probes^{17,18} and cGMP-based probes^{19,20} have been reported. However, the signals of enzymatic fluorescent probes reflect the accumulation of biochemical products and the activity of the total enzymes, rather than the target itself. The discovery of a proper fluorescent probe for detecting the intracellular profile of PDE5 is still a challenging task. The optical probes for tracing and imaging PDE5 were barely reported. Due to the highly conservative structure of catalytic domain in the PDE families, fluorescence labelled cyclic nucleotides may not be specifically recognized by the PDE enzymes, including PDE5. Moreover, many PDEs inhibitors do not have the characteristics of fluorescence, making them impossible to be used as fluorescent probes. Actually, it is still difficult to design a fluorescent probe

^aSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China. E-mail: gaoyuqi@thelilab.cn; gaoyq25@mail.sysu.edu.cn; luohb77@163.com; luohb77@mail.sysu.edu.cn

^bSchool of Pharmaceutical Sciences, Hainan University, Haikou 570228, China

† Electronic supplementary information (ESI) available: supplementary spectra and graphs and other data, materials and instruments, synthesis of probes PCO2001–2003, experiment section, characteristic of the compounds. See DOI: 10.1039/d1ra06247f

‡ These authors equally contributed to this work.






Fig. 1 Rational design of catalytic-site-fluorescent probe PCO2001–2003. For LW1607, $R_1 = R_2 = \text{H}$; PCO2001, $R_1 = \text{H}$, $R_2 = \text{OH}$; PCO2002, $R_1 = \text{NO}_2$, $R_2 = \text{OH}$; PCO2003, $R_1 = \text{NO}_2$, $R_2 = \text{H}$.

with a good PDE5 inhibitory and specificity based on the structures of PDE5 inhibitors.

To further understand the real-time distribution and manners of PDE5, especially in pulmonary tissues, we intended to design PDE5-targeting fluorescent probe. In our previous work, we discovered a series of PDE5 inhibitors with chromeno[2,3-*c*]pyrrol-9(2*H*)-one as the skeleton, which exhibited extraordinary inhibition towards PDE5.^{21,22} Surprisingly, LW1607, one of such PDE5 inhibitors, was capable of emitting blue fluorescence under the excitation at 365 nm. However, the capability of LW1607 for fluorescent imaging is still limited by the short-wavelength fluorescent emission and weak fluorescence intensity (Table S1, ESI†). With the help of molecular docking and molecular dynamics (MD) simulations, it is found that the pyrrole scaffold contributes to the excellent binding affinity to PDE5 protein while the chromone scaffold expands to the hydrophobic region where the space is enough for the substituents on the circle (Fig. S2, ESI†). Therefore, it is more suitable to introduce an electron-withdrawing group on the chromone scaffold in order to facilitate π -electron

delocalization for intramolecular charge transfer (ICT). With the purpose of preliminarily understanding the structure–activity relationship of these probes, we introduced different substituents to the 6- or 7-position of the chromone moiety to afford three compounds: PCO2001, PCO2002 and PCO2003, respectively. Perhaps we have to compromise on inhibitory activity to endow the compounds with the fluorescence. As shown in Table S1,† the introduction of hydroxyl at position C7 resulted in stronger inhibitions than LW1607, while PDE5 inhibitory activities exhibited weaker by substituting the C6 position with nitro group. It may imply that PDE5 inhibitory activities decreases with the electron density decreases in solvent region (Tables S2 and S3, ESI†). However, the probes become more environment-sensitive and the fluorescent imaging in living cells are better with the electron density decreases in solvent region. Finally, probe PCO2003 was selected for the subsequent experiments because of its excellent “turn-on” effects *in vitro*. It was also applied into detection and visualization of intracellular PDE5 and imaging of rat lung tissue slice, indicating the good ability to monitor PDE5 in a visible manner. This is the first attempt to endow a PDE5 inhibitor with fluorescent properties to establish the fluorescent probe to realize the visual track of the target protein (Fig. 1).




Fig. 2 (A) Fluorescent spectra of probe PCO2003 (10 μM) in PBS (1 \times , pH 7.4) when incubated with different concentration of recombinant PDE5A protein from 0 to 100 $\mu\text{g mL}^{-1}$. (B) The relative fluorescence intensity of probe PCO2003 (10 μM) in PBS when incubated with different concentration of recombinant PDE5 protein from 0 to 100 $\mu\text{g mL}^{-1}$. The fluorescence intensity was obtained at 558 nm. (C) Absorption and fluorescence spectra of PCO2003 in PBS and DMSO.




Fig. 3 Fluorescent images of live LX-2 cells stained with PCO2003 (10 μM) (A, D, G, J) and Hoechst 33342 (B, E, H, K). Fluorescent images of live LX-2 cells (A–C) as a control group; (D–F) LX-2 cells coincubated simultaneously with the PDE5A inhibitor dipyridamole (25 μM); (G–I) LX-2 cells coincubated simultaneously with the PDE5A inhibitor sildenafil (25 μM); (J–L) transiently transfected LX-2 cells with siRNA for the corresponding PDE5A knockdown group. The scale bar is 30 μm . For each sample, approximately 50 cells were measured.

Results and discussion

Design and synthesis

These fluorescent probes were well designed and synthesized on the base of the pattern of interaction between **LW1607** and the catalytic domain of PDE5. The detail synthesis procedure was explained in the ESI (Fig. S1†). All these probes could be predicted to have good electro-static interactions in allusion to amino acid residues of the catalytic pocket in PDE5 protein, contributing to the strong receptor-ligand binding patterns (Fig. S2, ESI†). These typical interactions include H-bond interactions for Y612 and Q817, and π - π interactions for F820 and F786. The pyrrole chromone scaffold matched well with the catalytic pocket in PDE5 protein contributing to a desired receptor-ligand binding pattern. The rigid and π -conjugated tricyclic conjugate scaffold is essential for the optical property.

Spectroscopic properties of the probes

All the probes performed the good environmentally sensitivity towards different polarity solvents (Table S1, Fig. S3 and S4, ESI†). The results suggested the potency of the compounds as a type of environment-sensitive turn-on probes. Exhibiting the excellent optical property among the three probes, **PCO2003** was selected for the subsequent experiments. When the probe **PCO2003** was incubated with recombinant PDE5 protein in PBS (1 \times , pH 7.4), the fluorescence intensity gradually increased with

the augmentation of the loaded amount of PDE5 protein, and reached more than 3-fold at the concentration of 0.1 mg mL⁻¹ over PBS (Fig. 2), indicating an excellent binding pattern between this probe and PDE5 as well as the potential of fluorescent imaging in cells and even tissues.

Visualization of PDE5 in live cells with **PCO2003**

Fluorescent imaging assays were conducted on LX-2, A549 and HeLa cells by laser-scanning confocal microscopy (LSCM). The human hepatic stellate cell line LX-2 was purchased from Procell Life Science Technology. The human lung carcinoma cell line A549 was purchased from American Type Culture Collection (ATCC). The human cervical carcinoma cell line HeLa was purchased from National Collection of Authenticated Cell Cultures. All the probes exhibited low cytotoxicity, indicating the good biological compatibility for bio-imaging assays (Fig. S5, ESI†). Except **PCO2001**, the other probes were capable to penetrate the membrane of live LX-2 cell and track PDE5 in a visible manner (Fig. S6 and S7, ESI†). In different cells, **PCO2003** showed augment fluorescence intensity in line with the increased intracellular expression levels of PDE5 (Fig. S8†). We also explored the interference of PDE5 inhibitors towards **PCO2003** (Fig. 3) and found that the fluorescent staining in live LX-2 cells was significantly influenced by sildenafil (PDE5, IC₅₀ = 2.5 nM) but not inhibited competitively by dipyrindamole (PDE5, IC₅₀ = 211 nM). Moreover, when LX-2 cells were transiently transfected with PDE5 siRNA to knock down the target protein before fluorescent imaging, the fluorescent signals of **PCO2003** declined obviously compared to the control group (Fig. 3 and S9, ESI†). The fluorescent imaging assays indicated the specificity of **PCO2003** towards PDE5 in live cells.

Tissue slice imaging with **PCO2003**

As is reported that some lung-related diseases such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) are associated with the up-regulation of PDE5,^{15,23,24} indicating the potency of PDE5 as the novel targets for the treatment of the diseases. Subsequently, we further explored the capability of **PCO2003** staining for rat pulmonary tissue slices. Apparently, the fluorescence signals of **PCO2003** as well as PDE5 fluorescent anti-antibody significantly increased in monocrotaline (MCT)-induced PAH tissues slices and bleomycin (BLM)-induced idiopathic pulmonary fibrosis tissues (C, F, I, L). In the orange boxes, the pulmonary artery was marked, while the pulmonary alveoli were marked in the cyan boxes.




Fig. 4 Immune fluorescence images of pulmonary tissue stained with PDE5A antibody (A–C), **PCO2003** (10 μ M) (D–F) and DAPI (G–I), as well as the merge images (J–L). The fluorescent images refer to normal pulmonary tissues (A, D, G, J), MCT-induced pulmonary arterial hypertension tissues (B, E, H, K) and BLM-induced idiopathic pulmonary fibrosis tissues (C, F, I, L). In the orange boxes, the pulmonary artery was marked, while the pulmonary alveoli were marked in the cyan boxes.

Conclusions

In summary, based on the insights into the ligand binding pocket of PDE5, three novel small-molecule fluorescent probes for PDE5 visualization were designed and synthesized. Among them, **PCO2003** exhibited reasonable fluorescent properties and high feasibility in detection and visualization of PDE5 protein. The results of bioactivity evaluation indicated the capability of the probe to fluorescent imaging in live cells and tissue slices. Moreover, the “turn-on” PDE5-specific fluorescent probe **PCO2003** is more convenient, rapid and economical as a visualization tool for PDE5, compared to the immunofluorescence or fluorescent protein-based techniques. These findings implying that the catalytic-site-fluorescent probe will have a variety of future applications in pathological and physiological studies as well as screening of other PDE5 inhibitors.

Conflicts of interest

The authors declare no competing financial interest.

Acknowledgements

This work was supported by Guangzhou Science and Technology Program (The People's Livelihood Programs for Science and Technology) (201803010075, 201904020023), China Postdoctoral Science Foundation (2019M663325), National Natural Science Foundation of China (81872727, 21877134, 81602955, 21702238, 81703341 and 82003576), Natural Science Foundation of Guangdong Province (2021A1515012499) and the Fundamental Research Funds for the Central Universities, Sun Yat-Sen University (2021qntd44).

Notes and references

- 1 S. Mizukami, S. Watanabe, Y. Hori and K. Kikuchi, Covalent Protein Labeling Based on Noncatalytic β -Lactamase and a Designed FRET Substrate, *J. Am. Chem. Soc.*, 2009, **131**, 5016–5017.
- 2 M. P. Patricelli, K. G. Dan, L. M. Stamp and J. J. Burbaum, Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes, *Proteomics*, 2015, **1**, 1067–1071.
- 3 M. P. Patricelli, T. K. Nomanbhoy, J. Wu, H. Brown, D. Zhou, J. Zhang, S. Jagannathan, A. Aban, E. Okerberg, C. Herring, B. Nordin, H. Weissig, Q. Yang, J.-D. Lee, N. S. Gray and J. W. Kozarich, In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases, *Chem. Biol.*, 2011, **18**, 699–710.
- 4 H. Zhu, J. Fan, J. Du and X. Peng, Fluorescent Probes for Sensing and Imaging within Specific Cellular Organelles, *Acc. Chem. Res.*, 2016, **49**, 2115–2126.
- 5 L. Chen, D. Wu and J. Yoon, An ES IPT based fluorescence probe for ratiometric monitoring of nitric oxide, *Sens. Actuators, B*, 2018, **259**, 347–353.
- 6 A. R. Lippert, E. J. New and C. J. Chang, Reaction-Based Fluorescent Probes for Selective Imaging of Hydrogen Sulfide in Living Cells, *J. Am. Chem. Soc.*, 2011, **133**, 10078–10080.
- 7 J. Yang, M. Fan, Y. Sun, M. Zhang, Y. Xue, D. Zhang, T. Wang and X. Cui, A near-infrared fluorescent probe based on phosphorus-substituted rhodamine for deep imaging of endogenous hypochlorous acid in vivo, *Sens. Actuators, B*, 2020, **307**, 127652.
- 8 G. Lv, B. Cui, H. Lan, Y. Wen, A. Sun and T. Yi, Diarylethene based fluorescent switchable probes for the detection of amyloid- β pathology in Alzheimer's disease, *Chem. Commun.*, 2014, **51**, 125–128.
- 9 Y. He, J. Yu, X. Hu, S. Huang, L. Cai, L. Yang, H. Zhang, Y. Jiang, Y. Jia and H. Sun, An activity-based fluorescent probe and its application for differentiating alkaline phosphatase activity in different cell lines, *Chem. Commun.*, 2020, **56**, 13323–13326.
- 10 H.-W. Liu, L. Chen, C. Xu, Z. Li, H. Zhang, X.-B. Zhang and W. Tan, Recent progresses in small-molecule enzymatic fluorescent probes for cancer imaging, *Chem. Soc. Rev.*, 2018, **47**, 7140–7180.
- 11 X. Wu, W. Shi, X. Li and H. Ma, Recognition Moieties of Small Molecular Fluorescent Probes for Bioimaging of Enzymes, *Acc. Chem. Res.*, 2019, **52**, 1892–1904.
- 12 K. Thérèse and L. Claire, Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments, *Br. J. Pharmacol.*, 2012, **165**, 1288–1305.
- 13 D. P. Rotella, Phosphodiesterase 5 inhibitors: current status and potential applications, *Nat. Rev. Drug Discovery*, 2002, **1**, 674–682.
- 14 N. Galiè, H. A. Ghofrani, A. Torbicki, R. J. Barst, L. J. Rubin, D. Badesch, T. Fleming, T. Parpia, G. Burgess, A. Branzi, F. Grimminger, M. Kurzyna and G. Simonneau, Sildenafil citrate therapy for pulmonary arterial hypertension, *N. Engl. J. Med.*, 2005, **353**, 2148–2157.
- 15 A. R. Hemnes, A. Zaiman and H. C. Champion, PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation, *Am. J. Physiol.: Lung Cell. Mol. Physiol.*, 2008, **294**, L24–L33.
- 16 H. K. Meilan, Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction, *Chest*, 2013, **143**, 1699–1708.
- 17 H. Takakusa, K. Kikuchi, Y. Urano, S. Sakamoto, K. Yamaguchi and T. Nagano, Design and synthesis of an enzyme-cleavable sensor molecule for phosphodiesterase activity based on fluorescence resonance energy transfer, *J. Am. Chem. Soc.*, 2002, **124**, 1653–1657.
- 18 C. M. Spangler, C. Spangler and M. Schäerling, Luminescent Lanthanide Complexes as Probes for the Determination of Enzyme Activities, *Ann. N. Y. Acad. Sci.*, 2010, **1130**, 138–148.
- 19 S. Matsuda, K. Harada, M. Ito, M. Takizawa, D. Wongso, T. Tsuboi and T. Kitaguchi, Generation of a cGMP Indicator with an Expanded Dynamic Range by Optimization of Amino Acid Linkers between a Fluorescent Protein and PDE5 α , *ACS Sens.*, 2017, **2**, 46–51.

- 20 M. L. Aulsebrook, M. Starck, M. R. Grace, B. Graham, P. Thordarson, R. Pal and K. L. Tuck, Interaction of Nucleotides with a Trinuclear Terbium(III)–Dizinc(II) Complex: Efficient Sensitization of Terbium Luminescence by Guanosine Monophosphate and Application to Real-Time Monitoring of Phosphodiesterase Activity, *Inorg. Chem.*, 2019, **58**, 495–505.
- 21 D. Wu, T. Zhang, Y. Chen, Y. Huang, H. Geng, Y. Yu, C. Zhang, Z. Lai, Y. Wu, X. Guo, J. Chen and H.-B. Luo, Discovery and Optimization of Chromeno[2,3-*c*]pyrrol-9(2*H*)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension, *J. Med. Chem.*, 2017, **60**, 6622–6637.
- 22 D. Wu, Y. Huang, Y. Chen, Y.-Y. Huang, H. Geng, T. Zhang, C. Zhang, Z. Li, L. Guo, J. Chen and H.-B. Luo, Optimization of Chromeno[2,3-*c*]pyrrol-9(2*H*)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure–Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension, *J. Med. Chem.*, 2018, **61**, 8468–8473.
- 23 S. Catalano, S. Panza, G. Augimeri, C. Giordano, R. Malivindi, L. Gelsomino, S. Marsico, F. Giordano, B. Gyórfy, D. Bonofiglio, S. Andò and I. Barone, Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression, *Cancers*, 2019, **11**, 1740.
- 24 R. T. Schermuly, S. S. Pullamsetti, G. Kwapiszewska, R. Dumitrascu, X. Tian, N. Weissmann, H. A. Ghofrani, C. Kaulen, T. Dunkern, C. Schudt, R. Voswinckel, J. Zhou, A. Samidurai, W. Klepetko, R. Paddenberg, W. Kummer, W. Seeger and F. Grimminger, Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy, *Circulation*, 2007, **115**, 2331–2339.